Share

August 11, 2015; 85 (6) Article

CIDP diagnostic pitfalls and perception of treatment benefit

Jeffrey A. Allen, Richard A. Lewis
First published July 15, 2015, DOI: https://doi.org/10.1212/WNL.0000000000001833
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1159

Share

Article Information

vol. 85 no. 6 498-504
DOI: 
https://doi.org/10.1212/WNL.0000000000001833
PubMed: 
26180143
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received December 22, 2014
  • Accepted in final form March 27, 2015
  • First Published July 15, 2015.

Article Versions

Copyright & Usage: 
© 2015 American Academy of Neurology

Author Disclosures

    1. Jeffrey A. Allen, MD and
    2. Richard A. Lewis, MD
  1. Jeffrey A. Allen, MD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Axcelacare (2) CSL Behring

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Richard A. Lewis, MD
    3. Scientific Advisory Boards:

    1. Novartis DSMB for trial of Gilenya in CIDP Steering Committee for CSL Behring Hizentra in CIDP trial

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Walgreen's for Barrow's Neuromuscular Colloquium

    Editorial Boards:

    1. Editorial Boards: Journal of Neurological Science Journal of Neuromuscular Disorders

    Patents:

    1. NONE

    Publishing Royalties:

    1. Up to Date: Article on CIDP

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Axelacare CSL Behring Noavartis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. I do EMGs for 30% of my activities

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (J.A.A.), University of Minnesota, Minneapolis; the Department of Neurology (J.A.A.), Northwestern University, Chicago, IL; and the Department of Neurology (R.A.L.), Cedars-Sinai Medical Center, Los Angeles, CA.
  1. Correspondence to Dr. Allen: jallen1{at}nmff.org
View Full Text

Article usage

Article usage: July 2015 to December 2020

AbstractFullPdfSource
Jul 2015603061Highwire
Aug 2015273599205Highwire
Sep 20155484777Highwire
Oct 20152663238Highwire
Nov 20152583646Highwire
Dec 20151762022Highwire
Jan 20162061828Highwire
Feb 20161631418Highwire
Mar 20161311614Highwire
Apr 20161121117Highwire
May 201693815Highwire
Jun 201612635Highwire
Jul 20161031616Highwire
Aug 20161131117Highwire
Sep 2016981012Highwire
Oct 20161231315Highwire
Nov 20161051315Highwire
Dec 20168999Highwire
Jan 20175927Highwire
Feb 20171211312Highwire
Mar 2017157915Highwire
Apr 201711138Highwire
May 2017105149Highwire
Jun 201766310Highwire
Jul 201714544Highwire
Aug 201710979Highwire
Sep 20171151115Highwire
Oct 20176297Highwire
Nov 201756915Highwire
Dec 201784138Highwire
Jan 2018135116Highwire
Feb 20181112017Highwire
Mar 201812898Highwire
Apr 20181341212Highwire
May 20181731011Highwire
Jun 20181732115Highwire
Jul 20181451011Highwire
Aug 20181631218Highwire
Sep 20181321111Highwire
Oct 20181511210Highwire
Nov 2018131117Highwire
Dec 201810165Highwire
Jan 2019123149Highwire
Feb 20191311411Highwire
Mar 2019112157Highwire
Apr 20191231312Highwire
May 2019136913Highwire
Jun 2019122911Highwire
Jul 201993910Highwire
Aug 20191292219Highwire
Sep 2019131914Highwire
Oct 20192311415Highwire
Nov 20192272923Highwire
Dec 20191441316Highwire
Jan 20201391411Highwire
Feb 20201191412Highwire
Mar 2020169179Highwire
Apr 20201551913Highwire
May 20201181614Highwire
Jun 20201081212Highwire
Jul 202012554Highwire
Aug 20207387Highwire
Sep 2020134109Highwire
Oct 20201452010Highwire
Nov 20201431611Highwire
Dec 2020162237Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me